In the interview Paul says we were monitoring the 600 patients in the dose escalation study for retinal damage due to elmiron's retinal damage assertions... no evidence at all of any damage in our 600 patients according to Paul.
Sharewise Presentation 22/7/24, page-117
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
-0.015(6.98%) |
Mkt cap ! $70.04M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 21.0¢ | 20.0¢ | $201.6K | 994.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 429247 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 13806 | 2 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |